Literature DB >> 15905987

[Quality assurance in the urologist's practice. Erectile dysfunction as an example of a multicenter approach to documenting treatment results].

K-P Jünemann1, S Cassens, H Lippert, M Burkart.   

Abstract

Of 517 urologist practices approached, 93% participated in a pilot study on the quality of care in the treatment of erectile dysfunction (ED). Treatment modalities and satisfaction were documented for 10,750 ED patients in 2002-at a time when vardenafil and tadalafil had not yet been officially approved. Psychological factors (55%), BPH (42%), and hypertension (33%) were given as the most prevalent ED risk factors; 82% of the patients received sildenafil, 20% apomorphine, 12% yohimbine, and 10% intracavernous alprostadil. Of the patients, 81% were satisfied or very satisfied with one of the treatment options offered and 85% and more were satisfied or very satisfied with sildenafil's onset of action, duration of action, efficacy, and tolerability. Of the physicians, 97% rated the opportunity to compare their own treatment results with other urologists' results as important or very important.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905987     DOI: 10.1007/s00120-005-0837-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

1.  [Guideline for diagnosis and therapy of libido and erectioni disorders. Guidelines of the German Society of Urology].

Authors: 
Journal:  Urologe A       Date:  2001-07       Impact factor: 0.639

2.  Guidelines on erectile dysfunction.

Authors:  Eric Wespes; Edouard Amar; Dimitrios Hatzichristou; Francesco Montorsi; John Pryor; Yoram Vardi
Journal:  Eur Urol       Date:  2002-01       Impact factor: 20.096

3.  [Quality management--should it remain as is or be changed? On the medical practice of a "learning organization"].

Authors:  T Radau
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

4.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

5.  Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use.

Authors:  J P Mulhall; A E Jahoda; A Ahmed; M Parker
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

6.  Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors.

Authors:  A T Guay; J B Perez; J Jacobson; R A Newton
Journal:  J Androl       Date:  2001 Sep-Oct

7.  Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire.

Authors:  R Lewis; C J Bennett; W D Borkon; W H Boykin; S E Althof; V J Stecher; R L Siegel
Journal:  Urology       Date:  2001-05       Impact factor: 2.649

8.  Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.

Authors:  O I Linet; F G Ogrinc
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

9.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

10.  Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital.

Authors:  Krishnamurthy Sairam; Elena Kulinskaya; Damian Hanbury; Gregory Boustead; Thomas McNicholas
Journal:  BMC Urol       Date:  2002-04-18       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.